Saudi Arabia seeks deeper multilateral cooperation for shared development, says foreign minister at BRICS summit    SAMA announces launch of new e-commerce payments interface    Alkhorayef emphasizes Saudi keenness on leveraging Russia's industrial expertise    Commercial registrations for holiday homes and chalets jump 42% in 2Q 2025    HADAF signs deal to support Saudis in hospitality and culinary arts fields    Saudi Arabia participates in UNCITRAL annual session in Vienna    HONOR returns to Esports World Cup as Official Smartphone Partner for 2025 The renewed commitment will see HONOR elevate mobile esports competition with cutting-edge AI technologies and industry-leading hardware    Trump calls Musk's new political party 'ridiculous'    Israel launches strikes on Houthi targets in Yemen    Central Nairobi sealed off ahead of Kenyan protests    81 dead and dozens missing in Texas floods as more rain looms    Saudi Arabia reaffirms dedication to achieving equitable and sustainable digital development    Saudi, British FMs discuss regional developments in phone call    Riot Games responds to match-fixing allegations in VALORANT    BLAST responds to BESTIA Visa controversy ahead of CS2 Austin major    Christophe Galtier named NEOM SC head coach ahead of historic Saudi Pro League debut    Michael Madsen, actor of 'Kill Bill' and 'Reservoir Dogs' fame, dead at 67    BTS are back: K-pop band confirm new album and tour    Michelin Guide launches in Saudi Arabia with phased rollout in 2025    'How fragile we are': Roskilde Festival tragedy remembered 25 years on    Sholay: Bollywood epic roars back to big screen after 50 years with new ending    Ministry launches online booking for slaughterhouses on eve of Eid Al-Adha    Shah Rukh Khan makes Met Gala debut in Sabyasachi    Pakistani star's Bollywood return excites fans and riles far right    Exotic Taif Roses Simulation Performed at Taif Rose Festival    Asian shares mixed Tuesday    Weather Forecast for Tuesday    Saudi Tourism Authority Participates in Arabian Travel Market Exhibition in Dubai    Minister of Industry Announces 50 Investment Opportunities Worth over SAR 96 Billion in Machinery, Equipment Sector    HRH Crown Prince Offers Condolences to Crown Prince of Kuwait on Death of Sheikh Fawaz Salman Abdullah Al-Ali Al-Malek Al-Sabah    HRH Crown Prince Congratulates Santiago Peña on Winning Presidential Election in Paraguay    SDAIA Launches 1st Phase of 'Elevate Program' to Train 1,000 Women on Data, AI    41 Saudi Citizens and 171 Others from Brotherly and Friendly Countries Arrive in Saudi Arabia from Sudan    Saudi Arabia Hosts 1st Meeting of Arab Authorities Controlling Medicines    General Directorate of Narcotics Control Foils Attempt to Smuggle over 5 Million Amphetamine Pills    NAVI Javelins Crowned as Champions of Women's Counter-Strike: Global Offensive (CS:GO) Competitions    Saudi Karate Team Wins Four Medals in World Youth League Championship    Third Edition of FIFA Forward Program Kicks off in Riyadh    Evacuated from Sudan, 187 Nationals from Several Countries Arrive in Jeddah    SPA Documents Thajjud Prayer at Prophet's Mosque in Madinah    SFDA Recommends to Test Blood Sugar at Home Two or Three Hours after Meals    SFDA Offers Various Recommendations for Safe Food Frying    SFDA Provides Five Tips for Using Home Blood Pressure Monitor    SFDA: Instant Soup Contains Large Amounts of Salt    Mawani: New shipping service to connect Jubail Commercial Port to 11 global ports    Custodian of the Two Holy Mosques Delivers Speech to Pilgrims, Citizens, Residents and Muslims around the World    Sheikh Al-Issa in Arafah's Sermon: Allaah Blessed You by Making It Easy for You to Carry out This Obligation. Thus, Ensure Following the Guidance of Your Prophet    Custodian of the Two Holy Mosques addresses citizens and all Muslims on the occasion of the Holy month of Ramadan    







Thank you for reporting!
This image will be automatically disabled when it gets reported by several people.



US FDA adviser resigns over approval of new Alzheimer's drug
Published in The Saudi Gazette on 10 - 06 - 2021

A member of a US Food and Drug Administration advisory committee said on Wednesday he had resigned over the agency's approval of a new Alzheimer's drug.
The FDA approved aducanumab, to be sold under the brand name Aduhelm, this week over the objections of its advisory Peripheral and Central Nervous System Drugs Advisory Committee.
Mayo Clinic neurologist Dr. David Knopman said on Wednesday he had resigned from the committee in protest.
"I resigned from the PCNS committee because if I ever were asked to serve on a future panel, I wouldn't have wanted to be treated in the disrespectful way that the aducanumab external advisers were treated," he said via email.
"While I disagree with the decision to approve aducanumab, we in the clinical care and clinical research worlds will simply have to learn to adapt to the new circumstances."
The FDA's advisers said there wasn't enough evidence to support approving the drug, which is given by infusion. Initial trials of the treatment, meant to be given to people very early in the course of disease before they develop dementia, did not indicate it helped at all. But the drug's maker, Biogen, re-analyzed data and said there was an indication it might help some patients.
The Washington Post first reported Knopman's resignation. A second member of the committee, Dr. Joel Perlmutter, did not immediately respond to CNN's queries about a report in STAT News he had also resigned.
The FDA had not approved a novel therapy for Alzheimer's disease since 2003. There is no cure for the disease, and current treatments can slow progression but none help for long. The Alzheimer's Association estimates that more than 6 million Americans have Alzheimer's related dementia.
Clinical trials of aducanumab were stopped in 2019 because they failed to show the drug was effective.
But the drug's maker, Biogen, re-analyzed the data and said it showed some patients who got high doses of the drug had not improved but had shown a slower rate of decline than other patients.
The PCNS committee met in November and voted on several questions about evidence of the drug's effectiveness.
They voted against the suggestion the drug could help patients, and came down as uncertain on the question of whether the drug had any effects on the brain.
While the FDA is not bound by the advice of its committees, it usually follows them, so the decision to approve the drug was unusual and controversial. Advocates for approval said the need is desperate, while opponents say the drug — priced at $56,000 a year — would bring in billions for Biogen while failing to help patients.
Aducanumab is a monoclonal antibody designed to pull a substance called amyloid out of the brain. Amyloid is one of the brain-clogging hallmarks of Alzheimer's, although Alzheimer's specialists are not in complete agreement about whether it's a cause or a symptom of the disease.
But the FDA decided the evidence showed the drug, given as an infusion, could reduce levels of amyloid in the brain and said this might help some patients.
The approval is for use in patients with mild cognitive impairment, which is the memory loss and loss of clear thinking ability that often progresses to dementia.


Clic here to read the story from its source.